About Us
Management Team
-
Greg Collier
-
Dennis Brown
-
Adam Craig
-
James Campbell
-
Rick Merrigan
-
Ian Nisbet
-
Tina Herbert
Board of Directors
-
Brett Heading
-
Greg Collier
-
Dennis Brown
-
Elmar Schnee
-
Geoff Brooke
-
Dan Janney
-
George Morstyn
-
Don Santel
-
Julie Cherrington
Scientific Advisory Board
-
Professor Ian Gust
-
Dr. Hagop Kantarjian
-
Dr. John Hughes
Clinical Advisors
R&D Leaders
-
Eric Humphriss
-
Shawnya Michaels
-
David Segal
Targeted Medicine
Strategic Alliances
Research Ethics
Our History
Pipeline
Omacetaxine mepesuccinate
Quinamed®
CXS-299
Cancer Discovery Program
Science & Technology
Drug Discovery & Preclinical Development
Genomic Clinical Development
Investors
ASX Information
Financial Reports
Corporate Governance
Presentation Archive
Information Request
News, Media, and Events
2008 Press Releases
2007 Press Releases
2006 Press Releases
2005 Press Releases
Investor Events Calendar
Clinical Trials
Chronic Myelogenous Leukemia
-
Omacetaxine mepesuccinate in T315I patients
-
Omacetaxine mepesuccinate in Multi-TKI Resistant Patients
-
Omacetaxine mepesuccinate plus Gleevec®
Myelodysplastic Syndrome
-
Omacetaxine mepesuccinate
Prostate Cancer
-
Amonafide Dihydrochloride (Quinamed®)
Careers
Culture
Current Openings
© 2005 ChemGenex Pharmaceuticals |
Terms of Use
